Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants
暂无分享,去创建一个
G. Kochs | G. Zimmer | M. Schwemmle | R. Grosse | R. Thimme | D. Wagner | M. Panning | S. Rieg | Lisa Kern | D. Schnepf | Y. Tanriver | M. Hofmann | J. Kemming | C. Neumann-Haefelin | H. Luxenburger | D. Huzly | D. Hornuss | V. Falcone | J. Beer | Jonas Fuchs | Sebastian Weigang | Svenja Ulferts | Jakob Ankerhold | Hendrik Luxenburger
[1] Rommie E. Amaro,et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma , 2021, Proceedings of the National Academy of Sciences.
[2] Ilya J. Finkelstein,et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes , 2021, Science.
[3] T. Ndung’u,et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma , 2021, Nature.
[4] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[5] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[6] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.
[7] G. Haidar,et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2021, Science.
[8] A. Sigal,et al. Sixteen novel lineages of SARS-CoV-2 in South Africa , 2021, Nature Medicine.
[9] Graham W. Taylor,et al. SARS-CoV-2 evolution during treatment of chronic infection , 2021, Nature.
[10] Vineet D. Menachery,et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis , 2021, Nature.
[11] T. Fülöp,et al. Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading? , 2021, Renal failure.
[12] Rommie E. Amaro,et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma , 2020, bioRxiv.
[13] William L. Hamilton,et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report , 2020, Nature Communications.
[14] W. P. Duprex,et al. Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2020, bioRxiv.
[15] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.
[16] E. Fischer,et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.
[17] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.
[18] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[19] Sarah K. Hilton,et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.
[20] S. Lehrer,et al. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 , 2020, In Vivo.
[21] Shamus P. Keeler,et al. SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.
[22] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[23] G. Zimmer,et al. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes , 2020, Vaccines.
[24] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[25] Samir Bhatt,et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil , 2020, Science.
[26] Anton Nekrutenko,et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2020 update , 2020, Nucleic Acids Res..
[27] P. Lemey,et al. Temporal signal and the phylodynamic threshold of SARS-CoV-2 , 2020, bioRxiv.
[28] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[29] D. Jans,et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.
[30] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[31] Young-Jun Park,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[32] P. Knolle,et al. TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation , 2017, Nature Communications.
[33] John Chilton,et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update , 2016, Nucleic Acids Res..
[34] A. von Haeseler,et al. IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies , 2014, Molecular biology and evolution.
[35] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[36] G. Zimmer,et al. A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon , 2011, PloS one.
[37] H. Niwa,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.
[38] O. Lund,et al. Access the most recent version at doi: 10.1110/ps.0239403 References , 2002 .
[39] D. C. Henckel,et al. Case report. , 1995, Journal.